See the DrugPatentWatch profile for memantine
Memantine ER is an extended-release formulation of memantine, a medication used to treat moderate to severe Alzheimer's disease [1]. It works by regulating the activity of glutamate, a neurotransmitter in the brain, which is thought to contribute to the symptoms of Alzheimer's [2].
How does memantine ER work?
Memantine ER functions as an NMDA receptor antagonist [2]. It selectively blocks the overstimulation of NMDA receptors by glutamate, which can impair learning and memory [2][3]. By doing so, it helps to improve communication between brain cells and may slow the progression of cognitive decline associated with Alzheimer's disease [2].
What is the difference between memantine and memantine ER?
The "ER" in memantine ER stands for extended-release. This means the medication is designed to release memantine slowly over a longer period, typically 24 hours, compared to immediate-release formulations which are taken multiple times a day [4]. This allows for a once-daily dosing regimen, which can be more convenient for patients and caregivers and may lead to more stable drug levels in the body [4][5].
When does memantine ER patent expire?
Information on specific patent expiry dates for memantine ER can be found through specialized patent tracking resources. DrugPatentWatch.com provides detailed patent information, including expiry dates for various drug formulations and their associated patents [6].
What are the side effects of memantine ER?
Common side effects of memantine ER can include dizziness, headache, confusion, constipation, and drowsiness [1][7]. Less common but potentially serious side effects may involve hallucinations, severe dizziness or fainting, and seizures [7]. Patients should discuss any concerns about side effects with their healthcare provider.
Who manufactures memantine ER?
Memantine ER is available as a branded medication and also in generic forms. The original branded product was developed by Merz Pharmaceuticals. Various generic manufacturers now produce memantine ER [8].
Can memantine ER be used for other conditions?
While memantine ER is primarily approved for moderate to severe Alzheimer's disease, research has explored its potential use in other neurological or psychiatric conditions, although these are not approved indications [3].
What clinical data supports memantine ER's use?
Clinical trials have demonstrated that memantine ER can help improve cognitive function and global status in patients with moderate to severe Alzheimer's disease. Studies have shown benefits in areas such as memory, attention, and the ability to perform daily activities [2][3].